Licdom Release Best | [updated]
| Feature | CREXONT (Oral Capsule) | RYTARY (Oral Capsule) | Lecigimon (Intestinal Gel) | Duodopa (Intestinal Gel) | | :--- | :--- | :--- | :--- | :--- | | | Moderate PD with motor fluctuations | Early to advanced PD | Advanced PD, severe fluctuations, dyskinesia | Advanced PD, severe fluctuations | | Mechanism | IR granules + ER beads (mucoadhesive) | Multiparticulate IR + ER beads | Triple combination (LD/CD/Entacapone) | LD/CD only | | Dosing Frequency | Approx. 3x/day | Approx. 4-5x/day | Continuous 24h infusion | Continuous daytime infusion | | Invasiveness | Non-invasive (oral) | Non-invasive (oral) | Invasive (PEG tube + pump) | Invasive (PEG tube + pump) | | Clinical Evidence | Very strong Phase 4 data; longest-lasting LD levels | Strong; longer track record | Emerging; slightly higher bioavailability vs. Duodopa | Strongest; gold standard for advanced PD | | Key Benefit | Longest duration of action per dose | Reliable, well-established | Triple-action with entacapone | Extensive real-world evidence | | Best Suited For | Patients with moderate fluctuations | Patients who need flexibility | Patients with refractory motor fluctuations | Patients failing other advanced therapies |

